drugset / Trial / NCT04269395

A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study

NCT04269395

Phase 3 Terminated 125 enrolled Galderma R&D
RandomizedParallel-groupDouble-blindPrevention

Summary

The primary purpose for this study is to assess recurrence of Actinic Keratosis in participants achieving complete response treated in earlier study.

Timeline

Start
2020-04-07
Primary completion
2021-09-01
Completion
2021-09-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator methyl aminolevulinate Small molecule

Indications